Tag Archives: business development

What’s Really Happening with the So-called ‘Blend Wall’? A Fuels America Briefing

Fuels-America-Briefing-July-11-Brent-1-300x200

The public dialog surrounding the Renewable Fuel Standard is robust- and filled with misinformation. On July 11, Rep. Lee Terry and Rep. Bruce Braley held the third of a series of briefings, which focused on what is really happening with the so-called ‘Blend Wall.’ The briefing consisted of five speakers, including BIO’s own Brent Erickson, Executive Vice President of the Industrial and Environmental Section. Opening remarks were given by Tom Buis, CEO of Growth Energy. Read More >

Biofuels & Climate Change  |  1 Comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Convention Post-Con, Plus a Look Ahead

Event Signs

Last month, the biopharma community gathered for the industry’s largest event, the BIO International Convention. We hope the event was successful for everyone who attended. We know it was a busy time for folks, especially based on the numbers from the Partnering System! Here is a quick recap: BIO One-on-One Partnering Stats for BIO2013 A total of 25,537 One-on-One Partnering meetings were scheduled at the event, officially beating last year’s record! Partnering Meeting Requests increased Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

State of the Biotech Industry: Burrill’s Biotech 2013 Report

Burrill

To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of attendees in the audience, saying after 45 years in the biotech industry, 27 years authoring the Burrill State-of-the-Industry Report and 20 years of presenting the report at Convention, he was determined to get through 228 slides in 90 minutes. And, he delivered, providing a comprehensive snapshot of the industry Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managed Entry Trumps Risk Sharing

Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Ernst & Young’s Beyond Borders: Matters of Evidence

Super Session

Hundreds of attendees turned out to glean insights from findings outlined in Ernst & Young LLP’s (EY) 27th annual report on the biotechnology industry – Beyond borders: matters of evidence – officially launched at Tuesday morning’s Super Session at the 2013 BIO International Convention. The report was presented by Glen Giovannetti and Gautam Jaggi of EY’s Global Life Sciences Center, and the Super Session featured a panel of industry leaders, including: Brian Edelman, VP, Corporate Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,